Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies.

导出 OA

翻译打印收藏纠错

作者： Sonia,Elhadad ^[1] ; David,Redmond ^[2] ; Adrian,Tan ^[3] ; Jenny,Huang ^[2] ; Beatriz Lorenzo,Rodriguez ^[1] ; Sabrina E,Racine-Brzostek ^[4] ; Sandeep,Subrahmanian ^[5] ; Jasimuddin,Ahamed ^[5] ; Jeffrey,Laurence ^[6]

作者单位： Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United States of America. ^[1] Division of Regenerative Medicine, Hartman Institute fort Therapeutic Organ Regeneration, Ansary Stem Cell Institute, United States of America. ^[2] Genomics Resources Core Facility, Weill Cornell Medicine, United States of America. ^[3] Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, United States of America. ^[4] Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America. ^[5] Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United States of America. Electronic address: jlaurenc@med.cornell.edu. ^[6]

关键词 COVID-19 Defibrotide Endothelial cell Long COVID Thrombosis Vasculopathy

主题词人类(Humans);半胱氨酸天冬氨酸蛋白酶8(Caspase 8);血管疾病(Vascular Diseases);内皮细胞(Endothelial Cells);造血干细胞移植(Hematopoietic Stem Cell Transplantation);抗凝药(Anticoagulants)

DOI 10.1016/j.thromres.2023.03.009

PMID 37001283

发布时间 2023-05-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交